In these survey 87 patients with influenza A (H1N1) were studied, involvement of both sexes was nearly identical. The majority of patients were Iranian, young and urbanites. The most common clinical symptom was fever cough and dyspnea.
In study of Li and Ma 48 of cases was male and 27 was female [
7]. In another study in China on 155 patients 90 (58.1%) were male [
8]. The involvement of male 148 (49.8%), and female 149 (50.2%) in study of Moghadami et al. like our study, was nearly identical [
6]. There was no sex preference in influenza. Regarding to influenza A (H1N1) was an emerging disease, all people were susceptible, and so this no sex difference is acceptable.
The most common physical finding was fever, tachycardia and tachypnea. In study on 63 children fever and tachypnea was the most common [
4]. The most important physical finding in influenza is fever which usually rapidly increases up to 40°C [
9].
In our study the mean age of patients was 30.1±18.5 years. The most patients were young and the elderly had lowest rate of disease (only 2 patients>76 years). In study of Nguyen-Van-Tam et al. also the most patient were young (36% under 16 years and 5% ≥ 65 years) [
10]. In study of Champunot et al. on 24 hospitalized patients, the mean age was 39.5 year [
11]. To et al. studied 186 influenza cases which 75% of influenza A (H1N1) was under 50 years [
12]. According above mentioned studies, the most patients in pandemic influenza A (H1N1) was the young adult which can be due to partial immunity of elderly resulting from past exposure in previous pandemic influenza [
13].
The mean of hospital stay was 4.13±2.7 days, this was 4 and 5 days in other studies [
5,
11] which are compatible with our study, so the hospital stay is the same duration of disease if no complication occurs [
9].
The most common clinical symptoms were fever, cough and dispend. Li and Ma and To et al. also reported these symptoms as the most common symptoms like our study [
7,
12], the cough is the most common and troublesome symptom of influenza [
9].
The most prominent laboratory findings were positive CRP, increased ESR and leukocytosis which these are markers of acute bacterial infection and their increase in influenza is unusual. Thrombocytopenia was found in 20% and increased keratinize in 20%, increased liver function test (LFT) in more than 80%, increased creatine phosphate kinase (CPK) (29.5%), LDH (73.7%). Ugarte also reported these changes [
5]. LDH was an independent risk factored for death [8]. In absence of mystic or myocarditis increase of CPK, LDH and LFT is important and check of them in Influenza should be considered.
Twenty-six (29.9%) patients had at least one comorbidity, the most common co morbidity was chronic renal failure. Study of Ugaret et al. showed 59% of patients had underlying disease which 25% of them were chronic renal failure [
5]. Calitri et al. reported that 29 (46%) of their patients had co morbidity [
4].
In present study 7 of 8 (87.5%) dead patients had underlying disease. Present study is relatively in accordance with that reported by Yang et al. which 50% of dead patients had underlying disease [
13]. According to fisher exact test there was found significant statistical correlation between final outcome and preexisting co morbidity.
Recovery was complete in 79 (90.8%) patients and 8 (9.2%) of patients died which 2 (22.2%) were in age group ≤5 years old. There was no seen death among patients 6 to 25 years. Li and Ma and Champunot et al. reported only one death [
7,
11] but 14.5% of patients died in study of Yang et al. [
13]. In other study in southern of Iran 11 (3.7%) out of 297 definitive case died [
6]. The mortality seen in our study is significantly higher than other studies preexisting co morbidity, delay in diagnosis and treatment may be important factors in different rate of death in different studies.
According to higher occurrence of mortality in individual with preexisting co morbidity, preventive measures through annual influenza vaccination and rapid treatment should be done in persons with underlying disease to prevent of mortality and morbidity of new emerging influenza virus.